Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
137 stopped studies mapped to Urinary Tract Carcinoma and descendants · 93% state a reason
Over the 137 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | Phase 2 | terminated | Aug 26, 2019 | Johannes Gutenberg University Mainz | Recruitment problems | Enrollment / accrual |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial… | Phase 2 | terminated | Feb 29, 2016 | M.D. Anderson Cancer Center | The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer. | Efficacy / futility |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Phase 2 | terminated | Jun 23, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle… | Phase 2 | terminated | Jun 5, 2012 | Fox Chase Cancer Center | Extreme Toxicity | Safety / toxicity |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of… | — | terminated | Jul 10, 2015 | University of Southern California | The PI left institution | Investigator |
| NCT02202044 | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After… | N/A | terminated | Jul 28, 2014 | University of Colorado, Denver | The institution was requiring extensive changes to the protocol | Other (stated, no rule matched) |
| NCT03029832 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in… | Phase 2 | terminated | Jan 24, 2017 | Genentech, Inc. | The study was prematurely terminated due to slow patient accrual and discontinuation of clinical… | Enrollment / accrual |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | N/A | terminated | Mar 4, 2016 | University of Southern California | PI decided to revamp the protocol completely and will submit as new study. | Other (stated, no rule matched) |
| NCT03399643 | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable…(Announce) | — | terminated | Jan 16, 2018 | Hoffmann-La Roche | Tecentriq label restriction for first line limited the patient population and scientific question… | Other (stated, no rule matched) |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in… | Phase 3 | withdrawn | May 8, 2015 | University of Southern California | No funding | Funding |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial… | Phase 2 | withdrawn | Feb 1, 2018 | University of California, San Francisco | Study withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure… | Phase 2 | terminated | Jan 8, 2015 | UNC Lineberger Comprehensive Cancer Center | Data from first 12 subjects-primary endpoint not met. Data analysis underway. | Other (stated, no rule matched) |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases… | Early Phase 1 | terminated | Jul 5, 2017 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02145390 | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant… | N/A | terminated | May 22, 2014 | University of Miami | Investigator Decision - Insufficient Accrual | Investigator |
| NCT01234519 | A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed… | Phase 1 / Phase 2 | terminated | Nov 4, 2010 | AEterna Zentaris | Poor recruitment | Enrollment / accrual |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | — | withdrawn | Aug 3, 2015 | University of Southern California | No funding | Funding |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for… | N/A | withdrawn | Aug 3, 2017 | University of Southern California | No funding | Funding |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With… | N/A | withdrawn | Oct 25, 2016 | Mayo Clinic | not stated | Not stated |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After… | Phase 2 | terminated | Jan 6, 2010 | University of Michigan | Study closed due to poor accrual | Enrollment / accrual |
| NCT01353222 | DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma | Phase 2 | terminated | May 13, 2011 | Dendreon | Administrative reasons. | Other (stated, no rule matched) |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Feb 19, 2010 | Hoosier Cancer Research Network | Lack of efficacy of experimental treatment | Efficacy / futility |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Jul 24, 2013 | University of Colorado, Denver | Sponsor's decision to terminate the study | Sponsor / business decision |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | Early Phase 1 | terminated | Nov 22, 2010 | University Hospital, Bordeaux | The rythm of enrollment was not compatible with the objective of recruitement in the research. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 30, 2021source: clinicaltrials